China-based venture capital firm Lilly Asia Ventures has received a commitment of $40 million for its fifth biosciences fund, LAV Biosciences Fund V, from San Francisco Employee’s Retirement System (SFERS), according to an investment report by the pension fund’s CIO.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
